Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-mat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yutani, Shigeru, Ueshima, Kazuomi, Abe, Kazumichi, Ishiguro, Atsushi, Eguchi, Junichi, Matsueda, Satoko, Komatsu, Nobukazu, Shichijo, Shigeki, Yamada, Akira, Itoh, Kyogo, Sasada, Tetsuro, Kudo, Masatoshi, Noguchi, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619935/
https://www.ncbi.nlm.nih.gov/pubmed/26539554
http://dx.doi.org/10.1155/2015/473909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619935/
https://www.ncbi.nlm.nih.gov/pubmed/26539554
http://dx.doi.org/10.1155/2015/473909

Ejemplares similares